Market Intelligence, Clinical Progress, and High-Purity Reagents for Neurological Disorder and Pain Management Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CACNA1A drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CACNA1A Extracellular Domain Peptides / Structural Proteins High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed. |
View CACNA1A Products |
| Gene Delivery | CACNA1A Full-Length ORF Lentivirus Premade Particles For stable cell line construction in HEK293 or neuronal backgrounds. Endotoxin Controlled. |
View CACNA1A Products |
| Benchmark Ab | Anti-CACNA1A Reference Antibody Recombinant positive control for binding assays. |
View CACNA1A Products |
| Validator | CACNA1A siRNA Set For knockdown verification and specificity controls. |
View CACNA1A Products |
| Related Target A | CACNA1C (L-Type Calcium Channel) Cardiac safety counter-screening; critical for selectivity assays. |
View CACNA1C Products |
| Related Target B | CACNB2 (Voltage-Gated Calcium Channel Beta-2 Subunit) Essential auxiliary subunit for CACNA1A trafficking and function. |
View CACNB2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| State-Dependent Binding (Open/Closed/Inactivated) | Full-Length Lentivirus for Stable Cell Lines preserving native conformation; Compatible with automated patch-clamp |
| Cross-Species Translation (Cyno/Mouse) | Human/Mouse/Cyno ortholog protein domains available with >95% purity; Sequence Verified |
| Subfamily Selectivity (P/Q vs L/N/R-type) | Homolog Panel (CACNA1A, CACNA1C, CACNA1B) strictly verified by mass spec for counter-screening |
| Auxiliary Subunit Dependence | Co-expression systems available; CACNB2 and CACNA2D2 complementary reagents provided |
| False Positives in Binding | Validated siRNA included for specificity checks and target engagement confirmation |
Live CACNA1A R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic landscape for CACNA1A is pivoting from symptomatic management of rare neurological disorders (Episodic Ataxia Type 2, Familial Hemiplegic Migraine Type 1, Spinocerebellar Ataxia Type 6) toward precision genetic medicines. The race for CACNA1A therapeutics is intensifying, with major players shifting focus from traditional small molecule blockers to precision genetic medicines (ASOs, RNAi) and highly selective peptide modulators. While small-molecule calcium channel modulators remain the standard of care, the next wave of R&D is dominated by Antisense Oligonucleotides (ASOs) targeting the CAG repeat expansion in SCA6 and gene therapy approaches for loss-of-function mutations. As first-generation ASO candidates enter clinical phases, the demand for robust cell-based assays utilizing full-length channel constructs has intensified to assess state-dependent pharmacology and off-target liability. Additionally, allele-specific silencing for SCA6 and precise gating modulation for FHM1 are key emerging areas.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ASO / Gene Therapy | Ionis Pharmaceuticals, Biogen, UniQure | SCA6, EA2 | Full-Length Functional Cell Lines (Lentivirus) for target engagement |
| Small Molecule Blockers | Biohaven Pharma, Zogenix | Migraine, Neuropathic Pain | State-Dependent Patch-Clamp (Selectivity vs CACNA1C) |
| Peptide Toxins (Derivatives) | Academic/Research Tools | Pain Research | High-Affinity Binding Assays (ECD domains) |
Molecular Differentiation & Assay Strategy
To achieve best-in-class profiles, drug candidates must demonstrate:
- State-Dependent Binding: Ideal P/Q channel modulators preferentially bind inactivated states during high-frequency firing and dissociate at rest. Automated patch-clamp assays using full-length CACNA1A stable cell lines (co-expressing CACNB2 and CACNA2D2) are essential.
- Subfamily Selectivity: Strict differentiation from Cav1.2 (cardiac toxicity) and Cav2.2 (N-type) is critical. Use homolog panels (CACNA1A, CACNA1C, CACNA1B) with mass-spec verified proteins for SPR/BLI counter-screening.
- Auxiliary Subunit Dependence: CACNA1A function requires beta and alpha2/delta subunits. Co-expression systems with CACNB2/CACNB4 and CACNA2D1/CACNA2D2 are recommended to study trafficking and gating modulation.
- Mutant Sensitivity: For inherited ataxias, maintain activity against mutants (CAG expansion in SCA6, truncation in EA2) while avoiding wild-type potentiation. Recombinant mutant proteins (R1668Q, S218L, D715E) for disease modeling are available.
TarMart provides Lentivirus Premade Particles for full-length channel expression, ensuring native glycosylation and membrane localization, plus validated siRNA and benchmark antibodies for assay development and specificity controls.